Processa Pharmaceuticals (PCSA) CAO buys 1,854 shares in open trade

Rhea-AI Filing Summary

Processa Pharmaceuticals Chief Administrative Officer Wendy Guy bought shares in the company. On the open market, she purchased 1,854 shares of common stock at $2.535 per share, increasing her direct holdings to 3,110 shares. She also has indirect ownership of 333 shares held by CorLyst, LLC.

Insider Trade Summary

Net Buyer: 1,854 shares ($4,700)

Net Buy 2 txns

Insider Guy Wendy

Role Chief Administrative Officer

Bought 1,854 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,854	$2.535	$5K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 3,110 shares (Direct); Common Stock — 333 shares (Indirect, By CorLyst, LLC)

Footnotes (1)

Key Figures

Shares purchased: 1,854 shares Purchase price: $2.535 per share Direct holdings after trade: 3,110 shares +1 more

4 metrics

Shares purchased 1,854 shares Open-market buy on common stock

Purchase price $2.535 per share Price for 1,854 purchased shares

Direct holdings after trade 3,110 shares Common stock directly owned by Wendy Guy

Indirect holdings 333 shares Common stock held indirectly through CorLyst, LLC

Key Terms

open-market purchase, indirect ownership, Form 4, common stock, +1 more

5 terms

open-market purchase financial

"She purchased 1,854 shares of common stock at $2.535 per share"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"She also has indirect ownership of 333 shares held by CorLyst, LLC"

Form 4 regulatory

"according to the Form 4 filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

common stock financial

"purchased 1,854 shares of common stock at $2.535 per share"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

CorLyst, LLC financial

"indirect ownership of 333 shares held by CorLyst, LLC"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guy Wendy

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Administrative Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		P		1,854	A	$2.535	3,110	D
Common Stock								333	I	By CorLyst, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Wendy Guy by John J. Wolfel, as Attorney-in-Fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PCSA executive Wendy Guy report?

Wendy Guy reported an open-market purchase of 1,854 Processa Pharmaceuticals shares. The transaction involved common stock acquired at $2.535 per share, increasing her direct ownership stake in the company to 3,110 shares according to the Form 4 filing.

At what price did PCSA executive Wendy Guy buy her shares?

She bought 1,854 Processa Pharmaceuticals common shares at $2.535 per share. This open-market purchase reflects the actual trade price disclosed and directly increased her personal equity exposure to the company as reported in the insider filing.

How many Processa (PCSA) shares does Wendy Guy own after this trade?

After the reported trade, she directly owns 3,110 common shares of Processa Pharmaceuticals. The filing also shows indirect ownership of 333 additional shares held through CorLyst, LLC, giving a fuller picture of her total reported exposure.

Is Wendy Guy’s PCSA shareholding direct or through another entity?

Her holdings are both direct and indirect. She directly owns 3,110 Processa Pharmaceuticals common shares, and indirectly holds 333 shares through CorLyst, LLC, as specified by the “By CorLyst, LLC” nature of ownership entry in the Form 4.

What type of transaction was reported in the PCSA Form 4 filing?

The main transaction was an open-market purchase of common stock, coded “P” on the Form 4. This indicates a buy in the market or a private transaction, rather than an option exercise, grant, or tax-related withholding event.